3 Specialty Generics Maker, Respiratory Medicines and Global Generics Leader and Injectables and Hospital Products Company Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals
- October 28, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals: ROE of 11.3% to 18.7% and FY22 to FY26 revenue CAGR of 7.1% to 12.1%. Prices as of 27 Oct 2026.
Quick Answer
The three respiratory and hospital medicine pharma stocks to watch are Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals. Their return on equity ranges from 11.3% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 12.1%. Emcure Pharmaceuticals leads on both return on equity at 18.7% and revenue growth at 12.1% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Respiratory and hospital medicine pharma stocks give investors a way to track businesses that sit close to everyday demand in India. Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals cover a specialty generics maker, a respiratory and global generics leader and a hospital medicines company.
This list covers three respiratory and hospital medicine pharma stocks with complete current figures: Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Respiratory and Hospital Medicine Pharma Stocks?
Respiratory and hospital medicine pharma stocks are listed pharmaceutical companies that make specialty generics, respiratory medicines and hospital and injectable products for India and export markets. Their earnings depend on product launches, regulatory approvals, pricing and currency.
Respiratory and Hospital Medicine Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 766.9 | 14,914 | 21.6 | 35.7 | 11.9 | 0.25 |
| Cipla | 1,350 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
| Emcure Pharmaceuticals | 1,875.2 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing respiratory and hospital medicine pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Respiratory and Hospital Medicine Pharma Stocks Have a Strong Roadmap in India?
Respiratory and hospital medicine pharma stocks have a strong roadmap in India because rising respiratory and chronic care needs, growing hospital networks and expanding exports keep widening the market for Indian pharmaceutical companies.
- Respiratory care. Inhaled therapies see rising demand.
- Hospital medicines. Growing hospitals need injectables.
- Exports. Overseas markets add scale.
Why Alembic Pharmaceuticals Features Among These Respiratory and Hospital Medicine Pharma Stocks
Among the respiratory and hospital medicine pharma stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.
The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.
Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore.
Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.
Why Cipla Features Among These Respiratory and Hospital Medicine Pharma Stocks
Among the generics, respiratory and injectables shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%.
In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Why Emcure Pharmaceuticals Features Among These Respiratory and Hospital Medicine Pharma Stocks
Among the three companies on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%.
Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Alembic Pharmaceuticals vs Cipla vs Emcure Pharmaceuticals on Key Financials
The table below sets the three respiratory and hospital medicine pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alembic Pharmaceuticals | 5,356 | 7,399 | 8.4% | 671 | 9.1% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Emcure Pharmaceuticals shows the fastest revenue growth with a 12.1% compound annual rate. A useful habit with respiratory and hospital medicine pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alembic Pharmaceuticals | 1,717 | 2,165 | 26.1% |
| Cipla | 7,216 | 7,330 | 1.6% |
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
Key Risks to Check Before Investing in Respiratory and Hospital Medicine Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these respiratory and hospital medicine pharma stocks, the main points are: Long-term generics, respiratory and injectables shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Currency moves. Export earnings move with the rupee.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter respiratory and hospital medicine pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Respiratory and Hospital Medicine Pharma Stocks
Respiratory and hospital medicine pharma stocks work best when investors track growth, valuation and return on equity side by side. Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals each have a clear plan to expand. Based on the 27 October 2026 close, Alembic Pharmaceuticals trades at Rs 766.9, Cipla at Rs 1,350 and Emcure Pharmaceuticals at Rs 1,875.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these respiratory and hospital medicine pharma stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track respiratory and hospital medicine pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are respiratory and hospital medicine pharma stocks?
Ans. Respiratory and hospital medicine pharma stocks are listed pharmaceutical companies that make specialty generics, respiratory medicines and hospital and injectable products for India and export markets. Their earnings depend on product launches, regulatory approvals, pricing and currency. This list looks at three of them, Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which respiratory and hospital medicine pharma stocks are covered in this list?
Ans. This list covers Alembic Pharmaceuticals, Cipla and Emcure Pharmaceuticals. Based on the 27 October 2026 close, Alembic Pharmaceuticals traded at Rs 766.9, Cipla at Rs 1,350 and Emcure Pharmaceuticals at Rs 1,875.2. Their return on equity ranges from 11.3% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 12.1%.
Why do respiratory and hospital medicine pharma stocks have a strong future roadmap in India?
Ans. Respiratory and hospital medicine pharma stocks have a strong roadmap in India because rising respiratory and chronic care needs, growing hospital networks and expanding exports keep widening the market for Indian pharmaceutical companies. The main drivers are as follows. Respiratory care. Inhaled therapies see rising demand. Hospital medicines. Growing hospitals need injectables. Exports. Overseas markets add scale. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alembic Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What risks should investors check before buying respiratory and hospital medicine pharma stocks?
Ans. Investors should check a few risks before buying respiratory and hospital medicine pharma stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Currency moves. Export earnings move with the rupee. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of respiratory and hospital medicine pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
